|
UNITED STATES
|
OMB APPROVAL
|
|
SECURITIES AND EXCHANGE COMMISSION
|
OMB Number: . . . . . 3235-0058
|
|
Washington, D.C. 20549
|
Expires: April 30, 2025
|
|
|
Estimated average burden hours
|
|
FORM 12b-25
|
per response. . . . . . . . 2.50
|
|
|
|
|
NOTIFICATION OF LATE FILING
|
|
|
|
SEC FILE NUMBER
|
|
|
001-24431
|
|
|
|
|
(Check one):
|
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
|
For Period Ended: March 31, 2023
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
☐ Transition Report on Form N-SAR
For the Transition Period Ended:__________________________________
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
PART I — REGISTRANT INFORMATION
ARTEMIS THERAPEUTICS, INC.
Full Name of Registrant
Former Name if Applicable
3 Eliezer Vardinon Street
Address of Principal Executive Office (Street and Number)
Petach Tikva, Israel 4959507
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if
appropriate)
|
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
|
☒
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following
the prescribed due date; and
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The registrant’s Quarterly Report on Form 10-Q for the three months ended March 31, 2023 cannot be filed within the prescribed time period because the registrant requires additional time to prepare
and finalize the financial statements for the period ended March 31, 2023. The registrant’s Quarterly Report on Form 10-Q will be filed on or before the 5th calendar day following the prescribed due date.
PART IV — OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
Shimon Citron
|
|
(972)
|
|
77-407-4700
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
Yes ☒ No ☐
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in
the subject report or portion thereof?
|
Yes ☐ No ☒
| |
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
|
|
|
ARTEMIS THERAPEUTICS, INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Date
|
May 15, 2023
|
|
By:
|
/s/ Shimon Citron
|
|
|
|
|
|
Shimon Citron
|
|
|
|
|
|
Chief Executive Officer and Director
|